Oltipraz, originally identified as an antischistosomiasis agent, is a potent anticarcinogen in a variety of animal models of cancer at concentrations of ~200 mg/kg. It is an effective inducer of phase I and II detoxifying enzymes, including glutathione S-transferases, UDP-glucuronosyltransferases, NAD(P)H:quinone...

ML-239 is an inhibitor of cancer stem cells, displaying greater than 23-fold selective inhibition of a breast cancer stem cell-like cell line (EC50 = 1.18 µM) over an isogenic control cell line (EC50 = 27.6 µM). It is also toxic to the breast carcinoma cell line MDA-MB-231. ML-239 alters the expression of genes in...

ML-180 is an inverse agonist of liver receptor homolog-1 (LRH-1, IC50 = 3.7 µM) with maximum efficacy of 64% repression. It is inactive at the related steroidogenic factor-1 transcriptional activator. Through LRH-1, ML-180 alters the expression of haptoglobin and serum amyloid proteins A1 and A4, induces the death...

5'-Ethynyl-2'-deoxycytidine (EdC) is a nucleoside analog that inhibits replication of the herpes simplex virus-1 (HSV-1) KOS strain (ID50 = 0.2 µg/mL). It also reduces virus-induced cytopathogenicity of HSV-1, HSV-2, and vaccinia virus strains in PRK cells (MICs = 0.2-0.4, 1-2, and 5 µg/ml, respectively). EdC is an...